Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24397807 | 0.89 | SLC6A2 (0.36) | LMNAHTTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29601371 | 0.89 | SLC6A2 (0.36) | LMNAHTTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24393970 | 0.86 | ALDH1A1 (0.39) | SLC6A2SLC6A4SLC6A3MAPTOPRM1 | |
| SCHEMBL24394120 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL26942730 | 0.83 | PPARD (0.36) | LMNAHTTSLC6A4SLC6A3MAPT | |
| SCHEMBL24394122 | 0.83 | FFAR4 (0.36) | LMNAHTTSLC6A4MAPT | |
| SCHEMBL26941611 | 0.82 | ALDH1A1 (0.37) | LMNAMAPT | |
| SCHEMBL26942762 | 0.82 | PDE2A (0.38) | LMNAHTTMAPTMRGPRX4 | |
| SCHEMBL24394026 | 0.81 | PPARD (0.36) | LMNAHTTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24393975 | 0.80 | KMT2A (0.38) | LMNAOPRM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| WO-2022090723-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | IL1R1, LRBA, HCAR1 | LMNA 3277/4885HTT 3422/4885SLC6A2 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.